The D44 Private Company Cocktail Reception during JPM

Satori Neuro is led by chief investment officer Dr. Amy Kruse, who has more than 20 years of experience in science, technology, and innovation, with a special focus on neurotechnology and human performance. Along with Satori principals’ operating experience in building and managing successful companies, Amy’s unique expertise, experience, and relationships give them a distinct advantage in recognizing the most promising and innovative businesses in the sector.

Satori’s focus is identifying the most promising companies and finding intersections where breakthrough treatments combine with disruptive business models to create value. Their stage-agnostic approach provides the flexibility to invest in what they believe to be the most compelling companies regardless of size and stage.

Request a Satori Neuro Company Presentation

Viage is developing the first-in-class oral drug candidate targeting the gut-brain axis.

Viage plans to initiate the Phase 2 program of DGX-001, which initially aim to achieve cognitive improvement across different diseases, representing a transdiagnostic study design, which may ultimately enable indications beyond neurology and psychiatry.

Viage’s pipeline is comprised of both novel neuropeptides and 2nd generation DGX-001-derived peptides and small molecules. It includes SAR-optimized drug candidates with potential in cognitive impairment, depression, anxiety, and inflammatory disease. The drug candidates are gut-acting and gut-restricted, which suggests an advantageous safety profile, particularly compared to most approved psychiatric drugs which suffer from numerous side effects.

Request a Viage Non-Confidential Company Presentation

Reconnect Labs is a Swiss Based Precision Neuropsychiatry Company.

Reconnect's pipeline and estimated clinical development timeline are depicted below. It notably consists of three near-term value inflection points ahead of a Series B.

RE03: The only drug candidate highly selective for stress-induced insomnias with a novel MoA that improves daytime function and restores regenerative, natural sleep by increasing and consolidating sleep architecture (NREM & REM sleep). A repurposed candidate, RE03 has robust clinical data demonstrating no risk of tolerance or dependence and showing improvements of comorbid psychiatric symptoms.

RE02: 5-MeO-DMT

A low-dose sublingual psycho-plastogen compatible with existing clinical routine and the potential for the first take-home Rx psychedelic API. Inherently more cost-effective and scalable best-in-class drug vs closest competitors. RE02 Phase 1 interim results show strong PK/PD dose response, sublingual bioavailability, rapid anxiolytic effects, and a highly tolerable PD profile at all dose levels. The promising results confirm the therapeutic potential of a non-psychedelic formulation with selective 5HT1A and neuro-plastogenic MoAs.

RE01: DMT / Harmine

Developed for Substance Use Disorders, it is highly differentiated to solve the cost, standardization and market access issues of gen 1 & 2 psychedelics, RE01 has shortened duration, removal of drug effect variability, removal of hallucinations, inebriation and AEs. SUD clinical infrastructure is well established but there is no pharmacotherapy SoC.

Request a Non-Confidential Reconnect Labs Investor Presentation

Cognigenics is at the forefront of advancing RNA-based therapeutics, revolutionizing treatment for mental health disorders.

Leveraging the precise application of short hairpin RNA (shRNA)-based therapeutics, their technology has demonstrated preclinical benefits in memory and anxiety.

Request a Cognigenics Non-Confidential Presentation

Tactogen is a mission-based and research-driven pharmatech company that uses machine learning and targeted assays to identify promising new medicines and new treatments. They seek to understand and leverage the ability of novel small molecules to improve health in a variety of contexts, including mental health and neurological problems.

Tactogen focuses on evaluating novel candidate molecules. Evaluation includes in vitro functional measures of mechanisms and in vivo estimation of therapeutic potential. They maximize our productivity and impact by collaborating with select academic partners and contract research organizations.

Request Non-Confidential Tactogen Company Presentation

Apollo Neuro has developed a wearable technology that is proven to improve mental health impacting mood, stress, and sleep through the body's response to touch. First incubated at the University of Pittsburgh, Apollo is backed by 6 clinical trials, has over 125K customers and growing, earned $10M in revenue last year and is on track for profitability in 2024, expects FDA clearance in 2025, and has a LOI in hand from a $200B+ pharma company for co/branding and co/marketing to a 50M person audience in 2025.

Request an Apollo Neuro Non-Confidential Company Presentation

Rivo Bio is an early-stage biotechnology company pioneering discovery of the next generation of neurohealth therapeutics through a unique systems-based approach integrating Computational Molecular Design and Rational Polypharmacology.

Rivo's initial focus is on the pathways underlying mental health, neurodegeneration, and cognitive impairment with early traction towards IP and hit/lead discovery. They have promising hit and lead-like novel compounds across multiple scaffolds identified, their first provisional patent filed Jan 2024, and they have proprietary strategies in place for increasing CNS availability and reducing peripheral toxicity

Request a Rivo Bio Non-Confidential Presentation

BrainTx's platform is focused on using AI computing to analyze neural imaging datasets to construct more objective, quantifiable, and translatable safety and efficacy models. The platform aims to reduce reliance on non-transferable animal models and misleading human cognitive testing which are long standing problems of drug development in neuroscience.

BrainTx's multifactorial phenotypic neuronal characterizations enable a streamlined path to efficient dose selections for first-in-human therapies, improving preclinical/clinical endpoint characterization, and accelerated time to market.

Request Non-Confidential Presentation

Brainify.AI is revolutionizing the antidepressant development process with their state-of-the-art neurotech solutions. By harnessing the power of AI and ML, they analyze EEG data to predict patient responses to treatments, effectively tackling the high placebo response rates and enhancing the success rates of Phase II and III clinical trials. Their technology further identifies patient subgroups most likely to benefit from specific drugs. This innovative approach not only improves drug efficacy but also solidifies patent claims, ensuring partners' treatments become the preferred first-line therapies.

Request a Non-Confidential Brainify Company Presentation